Cytiva, a global life sciences leader, is investing in additional resins manufacturing operations outside of Sweden, for the first time in the company’s history, with the acquisition of a new facility in Muskegon, Michigan. The new chromatography resins manufacturing site is part of Cytiva and Pall Corporation’s 1.5 billion USD capacity expansion investment.
Emmanuel Ligner, Danaher Group Executive and President and CEO of Cytiva, says: “This shows our leadership in action, strengthening our focus on providing customers who use our resins to manufacture vaccines and life-saving therapeutics.”
Cytiva plans to transform the site into a 168,000 square-foot biomanufacturing center consisting of multiple buildings. Cytiva will expand beyond Sweden to manufacture these resins, media that is critical in purifying and analyzing biomolecules so pharmaceutical and life sciences companies can make medicines. The facility will be home to approximately 200 associates when completed.
Governor Gretchen Whitmer of Michigan, says: “Cytiva’s investment in Muskegon will create good-paying jobs and build on West Michigan’s strength as a life sciences hub. I am thrilled that Cytiva is investing in Muskegon, and I look forward to further collaboration as we continue growing Michigan’s economy.”
“When you’re looking to help provide global biotechnology solutions to the world, it requires you to be nimble and flexible,” explains Ligner. “By investing in Muskegon, Michigan, we will be closer to our North American customers, who are developing advanced biotherapeutics.”
The site also benefits from the support of the Michigan Economic Development Corporation (MEDC), the Michigan Strategic Fund (MSF), and a co-operative agreement funded through the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, With contracting support from the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the U.S. Army Contracting command (ACC).
With a planned construction start date of Q3 2022, manufacturing is expected to begin in 2026.
Learn more about Cytiva’s resins and read about the industry insights uncovered in Cytiva’s Biopharma Resilience Index.
At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That’s why our 10,000+ associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them. We’re driven by their desire to achieve better flexibility, capacity, and efficiency in all facets of their work – all the way from idea to injection. Learn more at cytiva.com.
+1 774 245 3893